 NEWARK, Calif., Oct. 27, 2022 GLOBE NEWSWIRE -- Rain Therapeutics Inc. NasdaqGS: RAIN, Rain, a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT 5:00 pm ET to discuss the Companys business and financial results. 